Skip to main content
TipRanks
Go Ultimate75% OFF

Cel-Sci (LSR) AI Stock Analysis

0 Followers
DE:LSR

Cel-Sci

(Frankfurt:LSR)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Immunotherapy FocusCEL-SCI has a focused biotechnology strategy centered on immune-system modulation, with Multikine as its core development program. If clinical development succeeds, this specialized platform could support a differentiated position in cancer treatment and create long-term commercial opportunity.
Negative Factors
No Commercial RevenueZero reported revenue confirms that CEL-SCI has not yet demonstrated a commercial sales base. The business therefore remains dependent on successful development and commercialization of its programs, leaving revenue visibility, scalability, and operating self-sufficiency unproven.

Cel-Sci (LSR) vs. iShares MSCI Germany ETF (EWG)

-100%-80%-60%-40%-20%0%20%DE:LSR-71.74%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 29.20M
Dividend Yield
―
Average Volume (3M)
418
Price to Earnings (P/E)
-0.6
Beta (1Y)
1.97
Revenue Growth
―
EPS Growth
75.62%
Country
Germany
Employees
43
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Cel-Sci Business Overview & Revenue Model

Company Description

CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the t...

Cel-Sci Risk Analysis

Cel-Sci disclosed 39 risk factors in its most recent earnings report. Cel-Sci reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Cel-Sci Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:LSR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
UNCYUNCY45Neutral$103.06M-2.31-83.34%――44.11%
PLRXPLRX42Neutral$42.97M-0.47-58.31%――49.00%
ATHEATHE42Neutral$34.73M-2.04-48.25%――96.65%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:LSRATHEXBITPLRXUNCYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:LSR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:LSRCel-sci1.54-3.71-70.67%
ATHEAlterity Therapeutics1.96-1.64-45.56%
XBITXBiotech Inc.1.85-0.50-21.28%
PLRXPliant Therapeutics, Inc.0.69-0.88-55.86%
UNCYUnicycive Therapeutics, Inc.3.70-2.22-37.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.